ZYME FINANCIAL STATEMENTS

Zymeworks Inc. Common Stock — balance sheet, income statement and cash flow trends

ZYMEZymeworks Inc. Common Stock

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue81.3 M $-13.0%

Gross Profit76.7 M $-17.8%

Operating Income-114.1 M $—

EBITDA-94.3 M $—

Net Income-102.7 M $—

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
ZYME	-13.0%	94.4%	-116.1%	-126.3%
TLX	56.3%	50.8%	3.0%	-0.9%
MSB	410.4%	-32.0%	-76.6%	-115.3%
CSL	4.8%	48.6%	32.8%	9.2%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
ZYME	-13.0%	94.4%	-116.1%	-126.3%
VRDN	23,382.8%	99.4%	-492.7%	-508.5%
RXRX	11.0%	-34.4%	-723.3%	-844.5%
URGN	52.9%	89.9%	-82.4%	-94.8%
INVA	13.6%	76.2%	150.9%	118.9%
TYRA	-100.0%	—	—	—
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity163.6 M $34%
Current Liabilities35.6 M $7%
Long-term Liabilities279 M $58%

Key Figures

YoY change

Total Assets478.2 M $+12.4%

Total Liabilities314.6 M $+212.9%

Total Equity163.6 M $-49.7%

Cash & ST Investments364.7 M $+37.5%

Total Debt17 M $-7.7%

Net Debt-227.2 M $—

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
ZYME	10.82	10.4%	3.69	34.2%
TLX	1.43	112.3%	13.13	35.1%
MSB	—	—	—	—
CSL	2.57	67.4%	2.22	49.2%
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
ZYME	10.82	10.4%	3.69	34.2%
VRDN	15.15	8.0%	2.03	80.6%
RXRX	5.47	7.1%	1.21	76.5%
URGN	4.69	-158.6%	-0.48	-49.0%
INVA	21.13	24.7%	-0.44	73.1%
TYRA	20.49	1.5%	2.89	94.1%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow-75 M $—

Capital Expenditures2.1 M $-24.4%

Free Cash Flow-76.9 M $—

Dividends Paid——

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
ZYME	-92.3%	-94.6%	2.6%	73.1%
TLX	-2.2%	-6.3%	4.1%	243.1%
MSB	-87.7%	-90.0%	2.3%	76.1%
CSL	24.0%	20.3%	3.7%	261.5%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
ZYME	-92.3%	-94.6%	2.6%	73.1%
VRDN	-427.8%	-428.4%	0.6%	84.1%
RXRX	-484.2%	-491.6%	7.4%	57.3%
URGN	-118.0%	-118.2%	0.2%	124.4%
INVA	43.3%	42.6%	0.6%	36.4%
TYRA	—	—	—	78.0%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on ZYME

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.